NP-02
Neuropsychiatry (Unspecified)
N/ACompleted
Key Facts
About CNBX Pharmaceuticals
CNBX Pharmaceuticals is a clinical-stage biotech focused on discovering and developing cannabinoid-derived medicines for cancer and neuropsychiatric conditions. Its core strategy utilizes a proprietary drug discovery platform combining high-throughput screening and bioinformatics to identify potent cannabinoid formulations. The company's lead candidate, RCC-33 for colorectal cancer, is in late preclinical development, with a broader pipeline targeting melanoma, breast cancer, and neuropsychiatry. CNBX operates as a public entity, with its core R&D conducted through its Israeli subsidiary, Cannabics Pharmaceuticals.
View full company profileTherapeutic Areas
Other Neuropsychiatry (Unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| NP-01 | CNBX Pharmaceuticals | Discovery |